{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:13:48Z","timestamp":1783178028404,"version":"3.54.6"},"reference-count":33,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,8,1]]},"DOI":"10.2169\/internalmedicine.4685-24","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T17:11:46Z","timestamp":1738948306000},"page":"2369-2374","source":"Crossref","is-referenced-by-count":3,"title":["Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase \u03b1 to \u03b2 after Long-term ERT"],"prefix":"10.2169","volume":"64","author":[{"given":"Takuya","family":"Sugiura","sequence":"first","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Muto","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"},{"name":"Department of Renal Replacement Therapy, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Amano","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Handa City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Komaki City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayaho","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Katsuno","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Rheumatology, Aichi Medical University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritoshi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Higashi","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Numaguchi","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoyuki","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumitsu","family":"Sugiura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Fujita Health University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nphrol 15: 569-576, 2020.","DOI":"10.2215\/CJN.09480819"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Germain DP. Fabry disease. Orphanet J Rare Dis 5: 30, 2010.","DOI":"10.1186\/1750-1172-5-30"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shiga T, Tsukimura T, Kubota T, Togawa T, Sakuraba H. Globotriaosylceramide isoforms accumulated in body fluids from various phenotypic Fabry patients. Intern Med 63: 1531-1537, 2024.","DOI":"10.2169\/internalmedicine.2493-23"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry registry. Mol Genet Metab 93: 112-128, 2008.","DOI":"10.1016\/j.ymgme.2007.09.013"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Delaleu N, Marti HP, Strauss P, et al. Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. Kidney Int 104: 803-819, 2023.","DOI":"10.1016\/j.kint.2023.06.029"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Averbuch T, White JA, Fine NM. Anderson-Fabry disease cardiomyopathy: an update on epidemiology, diagnostic approach, management and monitoring strategies. Front Cardiovasc Med 10: 1152568, 2023.","DOI":"10.3389\/fcvm.2023.1152568"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ramaswani U. Update on role of agalsidase alfa in management of Fabry disease. Drug Des Devel Ther 5: 155-173, 2011.","DOI":"10.2147\/DDDT.S11985"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Lidove O, West ML, Pintos-Morell G, et al. Effects of enzyme replacement therapy in Fabry disease - a comprehensive review of the medical literature. Genet Med 12: 668-679, 2010.","DOI":"10.1097\/GIM.0b013e3181f13b75"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Keating GM. Agalsidase alfa: a review of its use in the management of Fabry disease. BioDrugs 26: 335-354, 2012.","DOI":"10.2165\/11209690-000000000-00000"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Limgala RP, Fikry J, Veligatla V, Goker-Alpan O. The interaction of innate and adaptive immunity and stabilization of mast cell activation in management of infusion related reactions in patients with Fabry disease. Int J Mol Sci 21: 7213, 2020.","DOI":"10.3390\/ijms21197213"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Utz JR, Doyen C, Whitley CB. Delayed infusion reactions to enzyme replacement therapy. Mol Genet Metab 93: S40, 2008.","DOI":"10.1016\/j.ymgme.2007.10.113"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Karimian Z, Whitley CB, Rudser KD, Utz JRJ. Delayed infusion reactions to enzyme replacement therapy. JIMD Rep 34: 63-70, 2017.","DOI":"10.1007\/8904_2016_8"},{"key":"13","unstructured":"13. Takeda Canada. Repragal<sup>\u00ae<\/sup> product monograph [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/assets-dam.takeda.com\/raw\/upload\/legacy-dotcom\/siteassets\/en-ca\/home\/what-we-do\/our-medicines\/product-monographs\/replagal\/replagal-pm-en.pdf."},{"key":"14","unstructured":"14. Sanofi Genzyme. Fabrazyme<sup>\u00ae<\/sup> (agalsidase beta) product monograph [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00038819.PDF."},{"key":"15","unstructured":"15. BMJ Best Practice. Assesment of hypotension 2024 [Internet]. [cited 2024 Sep 5]. Available from: https:\/\/bestpractice.bmj.com\/topics\/en-gb\/1196."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology 32: 498-502, 1982.","DOI":"10.1212\/WNL.32.5.498"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 13: 305-313, 2003.","DOI":"10.1093\/glycob\/cwg034"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Comparison of the effets of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 51: 180-188, 2006.","DOI":"10.1007\/s10038-005-0342-9"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Huby RD, Dearman RJ, Kimber I. Why are some proteins allergens? Toxicol Sci 55: 235-246, 2000.","DOI":"10.1093\/toxsci\/55.2.235"},{"key":"20","unstructured":"20. Bekri S. Importance of glycosylation in enzyme replacement therapy. In: Fabry Disease: Perspectives from 5 Years of FOS. Mehta A, Beck M, Sunder-Plassmann G, Eds. Oxford PharmaGenesis, Oxford, 2006."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tsuboi K, Yamamoto H. Clinical course of patients with Fabry disease who were switched from agalsidase-\u03b2 to agalsidase-\u03b1. Genet Med 16: 766-772, 2014.","DOI":"10.1038\/gim.2014.28"},{"key":"22","unstructured":"22. Barbey F, Livio F. Chapter 41. Safety of enzyme replacement therapy. In: Fabry Disease: Perspectives from 5 Years of FOS. Oxford PharmaGenesis, Oxford, 2006."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Mougenot P, Lidove O, Caillaud C, Arnaud P, Papo T. Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. Eur J Clin Pharmacol 64: 635-639, 2008.","DOI":"10.1007\/s00228-007-0460-8"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Lenders M, Nordbeck P, Canaan-K\u00fchl S, et al. Treatment switch in Fabry disease - a matter of dose? J Med Genet 58: 342-350, 2021.","DOI":"10.1136\/jmedgenet-2020-106874"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy. Clin Exp Nephrol 22: 843-849, 2018.","DOI":"10.1007\/s10157-017-1525-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Arends M, Wijburg FA, Wanner C, et al. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Mol Genet Metab 121: 157-161, 2017.","DOI":"10.1016\/j.ymgme.2017.05.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet 55: 351-358, 2018.","DOI":"10.1136\/jmedgenet-2017-104863"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Goker-Alpan O, Gambello MJ, Maegawa GHB, et al. Reduction of plasma globotriaosylsphingosine levels after switching from agalsidase alfa to agalsidase beta as enzyme replacement therapy for Fabry disease. JIMD Rep 25: 95-106, 2016.","DOI":"10.1007\/8904_2015_483"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Rombach SM, Dekker N, Bouwman MG, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta 1802: 741-748, 2010.","DOI":"10.1016\/j.bbadis.2010.05.003"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. van Breemen MJ, Rombach SM, Dekker N, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta 1812: 70-76, 2011.","DOI":"10.1016\/j.bbadis.2010.09.007"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Smid BE, van der Tol L, Biegstraaten M, Linthorst GE, Hollak CE, Poorthuis BJ. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet 52: 262-268, 2015.","DOI":"10.1136\/jmedgenet-2014-102872"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry&apos;s disease with the pharmacologic chaperone migalastat. N Engl J Med 375: 545-555, 2016.","DOI":"10.1056\/NEJMoa1510198"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Lenders M, Brand E. Precision medicine in Fabry disease. Nephrol Dial Transplant 36: 14-23, 2021.","DOI":"10.1093\/ndt\/gfab038"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4685-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:15:45Z","timestamp":1754108145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/15\/64_4685-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4685-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]},"article-number":"4685-24"}}